J&J Pharma R&D Taps Entelos for In Silico Studies of Type-2 Diabetes Therapies

Dec 19, 2007

NEW YORK (GenomeWeb News) - Entelos said today that has signed an agreement with Johnson & Johnson Pharmaceutical Research & Development to use its predictive computer models of human physiology to study new therapies for type-2 diabetes.

Under the agreement, Entelos will use its in silico “virtual patients” to discover and evaluate therapies for the disease.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Building Up Numbers

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Slow Coverage

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

Many Choices

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

This Week in Nature

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.

Main menu